The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers worldwide. The primary outcome measure is the improvement of clinical signs and symptoms of acute heart failure, with additional secondary outcome measures, including improvement in renal function.
Stan Abel, president and CEO of Corthera, said: “The clinical and preclinical results to date are very encouraging, demonstrating Relaxin’s beneficial hemodynamic properties.”